Clinical characteristics with patterns of relapse and survival analysis of ovarian clear cell carcinoma.
Loading...
Date
2016-04
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
AIMS: To analyze clinical characteristics, patterns of relapse, and treatment outcomes of clearcell carcinoma of the ovary (CCO). MATERIALS
AND METHODS: Case files of 51 patients diagnosed with CCO between 2003 and 2010 were reviewed. RESULTS: The median age at diagnosis
was 48 years (27-64 years). Fifty percent presented with nonspecific gastrointestinal symptoms. The median serum Ca125 was 74 IU/ml (6-1567
U/ml). Optimal cytoreduction was achieved in 32 (62.7%) patients. Of the 51 patients in this series, 34 (66.6%) had Stage I disease; Stage Ia in
12 (23.6%), Stage Ib in 1(1.9%), and Stage Ic in 21 (41.1%). Thirteen (25.6%) presented with Stage III and 4 (7.8%) with Stage IV. No patient had
Stage II disease. All patients received 4-6 cycles of platinum‑based combination chemotherapy. There were 18 relapses (35.2%), with disease‑free
intervals <6 months in 9, 6-12 months in 4, and >12 months in 5, respectively. Of them 33.3% had a recurrent pelvic mass. The median survival
after relapse was 14 months. There were 13 deaths, 11 due to disease progression, 1 due to chemo toxicity, and 1 unrelated to disease. At a
median follow up of 28 months, disease‑free survival (DFS) and overall survival (OS) of patients with Stage I-Stage II (early) disease was 64%
and 80%, respectively. In patients with advanced disease, that is, Stages III and IV, DFS and OS were 35% and 38%, respectively. CONCLUSION:
CCO generally presents at an early stage but has a high propensity for relapse. Patients with early‑stage disease have a relatively good prognosis
as compared with those with advanced‑stage disease.
Description
Keywords
Clear cell, ovary, relapse
Citation
Kaur S, Kerkar RA, Maheshwari A, Shylasree TS, Gupta S, Deodhar K. Clinical characteristics with patterns of relapse and survival analysis of ovarian clear cell carcinoma. Indian Journal of Cancer. 2016 Apr-June; 53(2): 288-291.